Sprycel Dose Reduction To Be Considered By Oncology Cmte. During ASCO Road Show
FDA’s Oncologic Drugs Advisory Committee will review Bristol-Myers Squibb’s data package for the Gleevec-resistant leukemia therapy dasatinib on June 2.
FDA’s Oncologic Drugs Advisory Committee will review Bristol-Myers Squibb’s data package for the Gleevec-resistant leukemia therapy dasatinib on June 2.